CDR substitutions of a humanized monoclonal antibody (CC49): Contributions of individual CDRs to antigen binding and immunogenicity

Molecular Immunology

Volumn 36, Issue 15-16, 1999, Pages 1079-1091

  Iwahashi, Makoto ^a   Milenic, Diane E ^a   Padlan, Eduardo A ^a   Bei, Roberto ^a   Schlom, Jeffrey ^a   Kashmiri, S V S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anti idiotypic antibodies; Antigen binding; Immunochemistry; Tumor immunity

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY CC49;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; IMMUNE RESPONSE; IMMUNOCHEMISTRY; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIGEN-ANTIBODY REACTIONS; BACULOVIRIDAE; BINDING SITES; BINDING, COMPETITIVE; CELL LINE; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; KINETICS; MICE; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS; SPODOPTERA;

EID: 0033368074     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(99)00094-2     Document Type: Article

References (69)

1. Abola E.E., Bernstein F.C., Bryant S.H., Koetzle T.F., Weng J. Protein data bank. Allen F.C., Bergerhoff G., Sievers R. Crystallographic Databases Information Content, Software Systems, Scientific Applications. 1987;107-132 Data Commission of the International Union of Crystallography, Bonn/Cambridge/Chester.
2. 177Lu-CC49: a Phase I/II study. Gyn. Oncol. 65:1997;94-101.
3. Bei R., Schlom J., Kashmiri S.V.S. Baculovirus expression of a functional single-chain immunoglobulin and its IL-2 fusion protein. J. Immunol. Methods. 186:1995;245-255.
4. Bell J., Mojzisik C., Hinkle G. Jr, Derman H., Schlom J., Martin E. Intraoperative radioimmunodetection of ovarian cancer using monoclonal antibody B72.3 and a portable gamma detecting probe. Obstet. Gynecol. 76:1990;607-611.
5. Bernstein F.C., Koetzle T.F., Williams G.J.B., Meyer E.F. Jr, Brice M.D., Rodgers J.R., Kennard O., Shimanouchi T., Tasumi M. The Protein Data Bank. A computer-based archival file for macromolecular structures. J. Mol. Biol. 112:1977;535-542.
6. Carayannopoulos L., Max E.E., Capra J.D. Recombinant human IgA expressed in insect cells. Proc. Natl. Acad. Sci. USA. 91:1994;8348-8352.
7. Chatenoud L., Jonker M., Villemain F., Goldstein G., Bach J.F. The human immune response to the OKT3 monoclonal antibody is oligoclonal. Science. 232:1986;1406-1408.
8. Cheetham G.M., Hale G., Waldmann H., Bloomer A.C. Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart. J. Mol. Biol. 284:1998;85-99.
9. Colcher D., Minelli F.M., Roselli M., Muraro R., Simpson-Milenic D., Schlom J. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res. 48:1988;4597-4603.
10. Colcher D., Milenic D.E., Ferroni P., Carrasquillo J.A., Reynolds J.C., Roselli M., Larson S.M., Schlom J. In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J. Nucl. Med. 31:1990;1133-1142.
11. D'Emilia J.C., Herlyn M., Schlom J., Gottlieb L.S., Steele G.D. Jr. Expression of colorectal carcinoma associated antigens in colonic polyps. J. Surg. Res. 55:1993;249-255.
12. Dersimonian H., Schwartz R.S., Barrett K.J., Stoller B.D. Relationship of human variable region heavy chain germ-line genes to genes encoding anti-DNA autoantibodies. J. Immunol. 139:1987;2496-2501.
13. Divgi C.R., Scott A.M., McDermott K., Fallone P.S., Hilton S., Siler K., Carmichael H., Daghighian F., Finn R.S., Cohen A.M., Schlom J., Larson S.M. Clinical comparison of radiolocalization of two monoclonal antibodies (MAbs) against the TAG-72 antigen. Nucl. Med. Biol. 21:1994;9-15.
14. Divgi C.R., Scott A.M., Dantis L., Capitelli P., Siler K., Hilton S., Finn R.D., Kemeny N., Kelsen D., Kostakoglu L., Schlom J., Larson S.M. Phase I Radioimmunotherapy trial with Iodine-131-CC49 in metastatic colon carcinoma. J. Nucl. Med. 36:1995;586-592.
15. 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma. Clin. Cancer Res. 1:1995;1503-1510.
16. Fan Z-C., Shan L., Goldsteen B.Z., Guddat L.W., Thakur A., Landolfi N.F., Co M.S., Vasquez M., Queen C., Ramsland P.A., Edmundson A.B. Comparison of the three-dimensional structures of a humanized and a chimeric Fab of an anti-γ-interferon antibody. J. Mol. Recog. 12:1999;19-32.
17. Ferroni P., Milenic D.E., Schlom J., Colcher D. Assay for the detection of anti-idiotypic antibodies to monoclonal antibody B72.3. J. Clin. Lab. Analysis. 4:1990;465-473.
18. Frankel M.E., Gerhard W. The rapid determination of binding constants for antiviral antibodies by a radioimmunoassay. An analysis of the interaction between hybridoma proteins and influenza virus. Mol. Immunol. 16:1979;101-106.
19. Fraker P.J., Speck J.C. Protein and cell membrane iodinations with a sparingly soluble chloramide 1,3,4,6-terachloro-3a,6a-diphenylglycouril. Biochem. Biophys. Res. Commun. 80:1978;849-857.
20. Glaser S.M., Vasquez M., Payne P.W., Schneider P.W. Dissection of the combining site in a humanized anti-Tac antibody. J. Immunol. 149:1992;2607-2614.
21. Greiner J.W., Dansky-Ullmann C.D., Nieroda C., Qi C-F., Eggensperger D., Shimada S., Steinberg S.M., Schlom J. Improved radioimmunotherapeutic efficacy of an anti-carcinoma monoclonal antibody (131I-CC49) when given in combination with IFN-γ Cancer Res. 53:1993;600-608.
22. Hale G.M., Dyer J.S., Clark M.R., Phillips J.M., Marcus R., Riechmann L., Winter G., Waldmann H. Remission induction in non-Hodgkins lymphoma with humanized monoclonal antibody CAMPATH-1H. Lancet. 2:1988;1394-1399.
23. Hearn M., Bethell G., Ayers J., Hancock W. Application of 1,1′-carbonyl-diimidazole-activated agarose for the purification of proteins. II. The use of an activated matrix devoid of additional charged groups for the purification of thyroid proteins. J. Chromatogr. 185:1979;463-470.
24. Holmes M.A., Foote J. Structural consequences of humanizing an antibody. J. Immunol. 158:1997;2192-2201.
25. Irvine K., Schlom J. Induction of delayed-type hypersensitivity responses by monoclonal anti-Id antibodies to tumor cells expressing carcinoembryonic antigen and tumor-associated glycoprotein-72. Cancer Immunol. Immunother. 36:1993;281-292.
26. Johnson V.G., Schlom J., Paterson A.J., Bennett J., Magnani J.L., Colcher D. Analysis of a human tumor-associtated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res. 46:1986;850-857.
27. Kabat E.A., Wu T.T., Perry H.M., Gottesman K.S., Foeller C. Sequences of Proteins of Immunological Interests. 5th ed. 1991;US Department of Health and Human Service, National Institutes of Health, Bethesda, MD. (NIH Publication No. 91-3242).
28. Kashmiri S.V.S., Hand P.H. Genetically engineered antitumor monoclonal antibodies. Garrett C., Sell S. Cellular Cancer Markers. 1995;393-432 Humana Press, Totowa, NJ.
29. Kashmiri S.V.S., Shu L., Padlan E.A., Milenic D.E., Schlom J., Hand P.H. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Hybridoma. 14:1995;461-473.
30. Kostakoglu L., Divgi C.R., Hilton S., Cordon-Cardo C., Scott A.M., Kalaigian H., Finn R.D., Schlom J., Larson S.M. Preselection of patients with high TAG-72 antigen expression leads to targeting of 94% of known metastatic tumor sites with monoclonal antibody I-131-CC49. Cancer Invest. 12:1994;551-558.
31. Kuroki M., Fernsten P.D., Wunderlich D., Colcher D., Simpson J.F., Poole D.J., Schlom J. Serologic mapping of the TAG-72 tumor-associated antigen employing 19 distinct monoclonal antibodies. Cancer Res. 50:1990;4872-4879.
32. Landt O., Grunert H.-P., Hahn U. A general method for rapid site-directed mutagenesis using the polymerase chain reaction. Gene. 96:1990;125-128.
33. Lin L., Gillies S.D., Lan Y., Izotova L., Wu W., Schlom J., Pestka S. Construction of phosphorylatable chimeric monoclonal antibody CC49. Int. J. Oncol. 13:1998;115-120.
34. 131I-CC49 radioimmunotherapy in three Phase II clinical trials. Cancer Biotherapy and Radiopharmaceuticals. 12:1997;79-87.
35. LoBuglio A.F., Wheeler R.H., Trang J., Haynes A., Rogers K., Harvey E.B., Sun L., Ghrayeb J., Khazaeli M.B. Mouse/human chimeric antibody in man: kinetics and immune response. Proc. Natl. Acad. Sci. USA. 86:1989;4220-4224.
36. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265.
37. 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial. Clinical Cancer Research. 3:1997;1547-1555.
38. Meredith R.F., Bueschen A.J., Khazaeli M.B., Plott W.E., Grizzle W.E., Wheeler R.H., Schlom J., Russell C.D., Liu T., LoBuglio A.F. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J. Nucl. Med. 35:1994;1017-1022.
39. Meredith R.F., Partridge E.E., Alvarez R.D., Khazaeli M.B., Plott G., Russell C.D., Wheeler R.H., Liu T., Grizzle W.E., Schlom J., LoBuglio A.F. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J. Nucl. Med. 37:1996;1491-1496.
40. Milenic D.E., Yokota T., Filpula D.L., Finkelman M.A.J., Dodd S.W., Wood J.F., Whitlow M., Snoy P., Schlom J. Construction, binding properties, metabolism and tumor targeting of a single-chain Fv derived from the pancarcinoma antibody CC49. Cancer Res. 51:1991;6363-6371.
41. Molinolo A., Simpson J.F., Thor A., Schlom J. Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor associated glycoprotein 72 monoclonal antibodies vs monoclonal antibody B72.3 in human tissue. Cancer Res. 50:1990;1291-1298.
42. Morrison S.L., Schlom J. Recombinant chimeric monoclonal antibodies. Rosenberg S.A. Important Advances in Oncology. 1989;3-18 Lippincott JB, Philadelphia, PA.
43. 177Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin. Cancer Res. 1:1995;1447-1454.
44. Muraro R., Kuroki M., Wunderlich D., Poole D.J., Colcher D., Thor A., Greiner J.W., Simpson J.F., Molinolo A., Noguchi P., Schlom J. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein-72 antigen. Cancer Res. 48:1988;4588-4596.
45. 131I-CC49 in colorectal cancer. Cancer. 73:1994;1057-1066.
46. Murray J.L., Macey D.J., Grant E.J., Rosenblum M.G., Kasi L.P., Zhang H.-Z., Katz R.L., Reiger P.T., LeBherz D., Bhadkamkar V., Greiner J.W., Schlom J., Podoloff D.A. Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha interferon treatment. Cancer Res. 55:1995;5925s-5928s.
47. Myers R.B., Schlom J., Srivastava S., Grizzle W.E. Expression of tumor-associated glyoprotein 72 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Mod. Path. 8:1995;260-265.
48. Nieroda C.A., Mojzisik C., Sardi A., Farrar W.B., Hinkle G., Siddiqi A., Ferrara P.J., James A., Schlom J., Thurston M.O., Martin E.W. Staging of carcinoma of the breast using a hand-held gamma detecting probe and monoclonal antibody B72.3. Surg. Gynecol. Obstet. 169:1989;35-40.
49. Padlan E.A. Anatomy of the Ab molecule. Mol. Immunol. 31:1994;169-217.
50. Padlan E.A., Abergel C., Tipper J.P. Identification of specificity-determining residues in Abs. FASEB J. 9:1995;133-139.
51. Reynolds J.C., Delvecchio S., Sakahara H., Lora M. Anti-murine response to mouse monoclonal antibodies. Nucl. Med. Biol. 16:1989;121-125.
52. Riechmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature. 332:1988;323-327.
53. Russoniello C., Somasundaram C., Schlom J., Deo Y.M., Keler T. Characterization of a novel bispecific antibody that mediates FcgRI-dependent killing of TAG-72-expressing tumor cells. Clinical Cancer Research. 4:1998;2237-2243.
54. Salem R.R., Wolf B.C., Sears H.F., Lavin P.T., Ravikuman T.S., DeCoste D., D'Emilia J.C., Herlyn M., Schlom J., Gottlieb L.S., Steele G.D. Jr. Expression of colorectal carcinoma Ags in chronic polyps. J. Surg. Res. 55:1993;249-255.
55. Salgaller M.L., Bei R., Schlom J., Poole D.J., Robbins P.F. Baculovirus recombinants expressing the human carcinoembryonic antigen gene. Cancer Res. 53:1993;2154-2161.
56. Scatchard G. The attractions of proteins for small molecules and ions. Ann. NY Acad. Sci. 51:1949;660-672.
57. Schlom J., Eggensperger D., Colcher D., Molinolo A., Houchens D., Miller L.S., Hinkle G., Siler K. Therapeutic advantage of high affinity anti-carcinoma radioimmunoconjugates. Cancer Res. 52:1992;1067-1072.
58. Schlom J., Milenic D.E., Siler K., Yokota T., Kashmiri S.V.S., Horan Hand P. Advances in monoclonal antibody-guided radioimmunotherapy and diagnosis of cancer. Huber B.E. Cancer Therapy into the Twenty First Century. 1994;181-210 Futura Publishing Co, Inc, Mount Kisco, NY.
59. Schneider M., Hilschmann N. The primary structure of a monoclonal immunoglobulin L-chain of the κ-type, subgroup IV (Bence-Jones Protein LEN): a new subgroup of the κ-type L-chain. Hoppe-Seyler's Z. Physiol. Chem. 355:1974;1154-1168.
60. 3. J. Immunol. 150:1993;3086-3090.
61. Schott M.E., Milenic D.E., Yokota T., Whitlow M., Wood J.F., Fordyce W.A., Cheng R.C., Schlom J. Differential metabolic patterns of iodinated vs radiometal chelated anticarcinoma single-chain Fv molecules. Cancer Res. 52:1992;6413-6417.
62. Sears H.F., Herlyn D., Steplewski Z., Kaprowski H. Effects of antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J. Biol. Res. Mod. 3:1984;138-150.
63. Seccamani E., Tattanelli M., Mariani M., Spranzi E., Scassellati G.A., Siccardi A.G. A simple quantitative determination of human antibodies to murine immunoglobulins (HAMA) in serum samples. Nucl. Med. Biol. 16:1989;167-170.
64. Shawler D.L., Bartholomew R.M., Smith L.M., Dilman R.O. Human immune response to multiple injections of murine monoclonal IgG. J. Immunol. 135:1985;1530-1535.
65. Slavin-Chiorini D., Kashmiri S.V.S., Lee H.-S., Milenic D., Poole D., Bernon E., Schlom J., Horan Hand P. A CDR-grafted (humanized) domain-deleted antitumor antibody. Cancer Biotherapy & Radiopharmaceuticals. 12:1997;305-316.
66. 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clin. Cancer Res. 4:1998;643-651.
67. Tempero M., Leichner P., Dalrymple G., Harrison K., Augustine S., Schlom J., Wisecarver J., Colcher D. High dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. J. Clin. Oncol. 15:1997;1518-1528.
68. Thor A., Itzkowitz H., Schlom J., Kim Y.S., Hanauer S. Tumor associated glycoprotein (TAG-72) expression in ulcerative colitis. Int. J. Cancer. 43:1989;810-815.
69. Winter G., Harris W.J. Humanized antibodies. Immunol. Today. 14:1993;243-246.